|
|
| Line 1: |
Line 1: |
| {{Infobox diagnostic | | {{Short description|Patient-reported outcome measure for rheumatoid arthritis}} |
| | name = The Rheumatoid Arthritis Quality of Life Questionnaire | |
| | image =
| |
| | alt =
| |
| | caption =
| |
| | pronounce =
| |
| | purpose =determine quality of life with Rheumatoid Arthritis
| |
| | test of =
| |
| | based on =
| |
| | synonyms =
| |
| | reference_range =
| |
| | calculator =
| |
| | DiseasesDB = <!--{{DiseasesDB2|numeric_id}}-->
| |
| | ICD10 = <!--{{ICD10|Group|Major|minor|LinkGroup|LinkMajor}} or {{ICD10PCS|code|char1/char2/char3/char4}}-->
| |
| | ICD9 =
| |
| | ICDO =
| |
| | MedlinePlus = <!--article_number-->
| |
| | eMedicine = <!--article_number-->
| |
| | MeshID =
| |
| | OPS301 = <!--{{OPS301|code}}-->
| |
| | LOINC = <!--{{LOINC|code}}-->
| |
| }}
| |
| '''The Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)''' is a disease specific [[patient-reported outcome]] measure which determines the effect [[rheumatoid arthritis]] has on a patient’s [[quality of life]].<ref>{{cite journal|last=de Jong|first=Z. |author2=van der Heijde, D. |author3=McKenna, S.P. |author4=Whalley, D. |title=The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.|journal=Rheumatology|year=1997|volume=36|issue=8|pages=878–883|doi=10.1093/rheumatology/36.8.878|url=http://rheumatology.oxfordjournals.org/content/36/8/878.abstract|accessdate=30 September 2013}}</ref> The RAQoL has 30 items with a yes and no response format<ref>{{cite journal|last=Adams|first=Jo|author2=Chapman, Judith |author3=Bradley, Sarah |author4= Ryan, Sarah Jane |title=Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology|journal=Rheumatology|year=2013|volume=52|issue=3|pages=460–464|doi=10.1093/rheumatology/kes296|url=http://rheumatology.oxfordjournals.org/content/52/3/460.abstract|accessdate=30 September 2013|pmid=23118412}}</ref> and takes about six minutes to complete.<ref>{{cite journal|last=de Jong|first=Z. |author2=van der Heijde, D. |author3=McKenna, S.P. |author4=Whalley, D. |title=The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.|journal=Rheumatology|year=1997|volume=36|issue=8|pages=878–883|doi=10.1093/rheumatology/36.8.878|url=http://rheumatology.oxfordjournals.org/content/36/8/878.abstract|accessdate=30 September 2013}}</ref>
| |
|
| |
|
| Scores on the RAQoL are a sum of all the individual item scores with a range from 0-30, with a lower score indicating better quality of life.<ref>{{cite journal|last=Tijhuis|first=G.J. |author2=de Jong, Z. |author3=Zwinderman, A.H. |author4=Zuijderduin, W.M. |author5=Jansen, L.M.A. |author6=Hazes, J.M.W. |author7=Vliet Vlieland, T.P.M. |title=The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire|journal=Rheumatology|year=2001|volume=40|issue=10|pages=1112–1119|doi=10.1093/rheumatology/40.10.1112|url=http://rheumatology.oxfordjournals.org/content/40/10/1112.abstract|accessdate=30 September 2013}}</ref> The RAQoL is a self-assessment [[questionnaire]], meaning patients fill out the survey themselves in order to avoid experimental error.<ref>{{cite journal|last=Maska|first=L.|author2=Anderson, J. |author3=Michaud, K. |title=Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL).|journal=Arthritis Care & Research |date=November 2011 |volume=63|issue=Supplement S11|pages=S4–S13|doi=10.1002/acr.20620|pmid=22588760}}</ref>
| | '''Rheumatoid Arthritis Quality of Life Questionnaire''' ('''RAQoL''') is a disease-specific, patient-reported outcome measure designed to assess the impact of [[rheumatoid arthritis]] (RA) on a patient's [[quality of life]]. The RAQoL is widely used in clinical practice and research settings to understand how RA affects daily functioning, emotional well-being, and overall patient satisfaction with life. |
|
| |
|
| == History == | | ==Purpose== |
| | The primary purpose of the RAQoL is to quantitatively measure the patient's own perspective regarding how rheumatoid arthritis influences their day-to-day life, emotional health, social interactions, and ability to perform regular tasks. As a self-administered instrument, it helps ensure accuracy by minimizing experimenter bias or error. |
|
| |
|
| The RAQoL was developed by Galen Research, the [[University of Leeds]] and the [[Academic Hospital Maastricht]], and was first published in 1997.<ref>{{cite journal|last=Whalley|first=D. |author2=McKenna, S.P. |author3=de Jong, Z. |author4=van der Heijde, D. |title=Quality of life in rheumatoid arthritis.|journal=Rheumatology|year=1997|volume=36|issue=8|pages=884–888|doi=10.1093/rheumatology/36.8.884|url=http://rheumatology.oxfordjournals.org/content/36/8/884.abstract|accessdate=30 September 2013}}</ref> It was the first patient completed quality of life questionnaire that focused on rheumatoid arthritis <ref>{{cite journal|last=Marra|first=Carlo A.|author2=Woolcott, John C. |author3=Kopec, Jacek A. |author4=Shojania, Kamran |author5=Offer, Robert |author6=Brazier, John E. |author7=Esdaile, John M. |author8= Anis, Aslam H. |title=A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.|journal=Social Science & Medicine|date=April 2005|volume=60|issue=7|pages=1571–1582|doi=10.1016/j.socscimed.2004.08.034|pmid=15652688}}</ref> and is distinct from other questionnaires as it includes physical contact as a dimension of quality of life.<ref>{{cite journal|last=Tijhuis|first=G.J. |author2=de Jong, Z. |author3=Zwinderman, A.H. |author4=Zuijderduin, W.M. |author5=Jansen, L.M.A. |author6=Hazes, J.M.W. |author7=Vliet Vlieland, T.P.M. |title=The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire|journal=Rheumatology|year=2001|volume=40|issue=10|pages=1112–1119|doi=10.1093/rheumatology/40.10.1112|url=http://rheumatology.oxfordjournals.org/content/40/10/1112.abstract|accessdate=30 September 2013}}</ref> Other dimensions include activities of daily living, social interaction/function, emotions, mood and recreation and pastimes.<ref>{{cite journal|last=Lillegraven|first=Siri|author2=Kvien, Tore K. |title=Measuring disability and quality of life in established rheumatoid arthritis.|journal=Best Practice & Research Clinical Rheumatology.|date=October 2007|volume=21|issue=5|pages=827–840|doi=10.1016/j.berh.2007.05.004|pmid=17870030}}</ref>
| | ==Structure== |
| | The RAQoL questionnaire consists of '''30 items''', each answered with a simple '''"yes" or "no"''' response. The questionnaire is designed to be concise and patient-friendly, generally taking approximately '''six minutes''' for a patient to complete. This brief and straightforward format allows ease of use in both clinical and research environments. |
|
| |
|
| == International Use ==
| | Each of the 30 items reflects a specific area of life potentially impacted by rheumatoid arthritis, including physical function, emotional health, social participation, and general daily activities. |
|
| |
|
| Since its development, the RAQOL has been translated into 33 languages other than Dutch and UK English.<ref>{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|work=Galen-Research.com|publisher=Galen Research|accessdate=2 October 2013}}</ref> Validation studies have been performed in countries such as Sweden,<ref>{{cite journal|last=Eberhardt|first=Kerstin|author2=Duckberg, Siv |author3=Larsson, Britt-Marie |author4=Johnson, Pia Malcus |author5= Nived, Kerstin |title=Measuring health related quality of life in patients with rheumatoid arthritis – reliability, validity, and responsiveness of a Swedish version of RAQoL.|journal=Scandinavian Journal of Rheumatology|date=July 2009|volume=31|issue=1|pages=6–12|doi=10.1080/030097402317255291|pmid=11922201}}</ref> Argentina<ref>{{cite journal|last=Waimann|first=Christian A. |author2=Dal Pra, Fernando M. |author3=Marengo, Maria F. |author4=Schneeberger, Emilce E. |author5=Gagliardi, Susana |author6=Maldonado Cocco, Jose A. |author7=Sanchez, Monica |author8=Garone, A. |author9=Chaparro del Moral, Rafael E. |author10=Rillo, Oscar L. |author11=Salcedo, Mariana |author12=Rosa, Javier E. |author13=Ceballos, F. |author14=Soriano, Enrique R. |author15=Citera, Gustavo |title=Quality of life of patients with rheumatoid arthritis in Argentina: reliability, validity, and sensitivity to change of a Spanish version of the Rheumatoid Arthritis Quality of Life questionnaire.|journal=Clinical Rheumatology|date=July 2012|volume=31|issue=7|pages=1065–1071|doi=10.1007/s10067-013-2397-x|pmid=24158632 |url=https://link.springer.com/article/10.1007%2Fs10067-012-1976-6|accessdate=2 October 2013}}</ref> and Australia<ref>{{cite journal|last=Cox|first=S.R.|author2=McWilliams, L. |author3=Massy-Westropp, N. |author4=Meads, D.M. |author5=McKenna, S.P. |author6= Proudman, S. |title=Adaptation of the RAQoL for use in Australia|journal=Rheumatology International|date=May 2007|volume=27|issue=7|pages=661–666|doi=10.1007/s00296-006-0287-0|pmid=17195065}}</ref> in order to confirm the responsiveness and validity of the language adaptations.
| | ==Scoring== |
| | The scoring method of the RAQoL is straightforward and easy to interpret: |
|
| |
|
| The RAQoL has been used in [[clinical studies]] in order to confirm the efficacy of proposed treatments of rheumatoid arthritis. It has been utilized in order to confirm the efficacy of [[tocilizumab]]<ref>{{cite journal|last=Dougados|first=Maxime |author2=Kissel, Karsten |author3=Sheeran, Tom |author4=Tak, Paul P. |author5=Conaghan, Philip G. |author6=Mola, Emilio Martin |author7=Schett, Georg |author8=Amital, Howard |author9=Navarro-Sarabia, Federico |author10=Hou, Antony |author11=Bernasconi, Corrado |author12=Huizinga, TWJ |title=Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)|journal=Annals of the Rheumatic Diseases|year=2013|volume=72|issue=1|pages=43–50|doi=10.1136/annrheumdis-2011-201282 |pmc=3551223|pmid=22562983}}</ref><ref>{{cite journal|title=Efficacy of tocilizumab in patients with rheumatoid arthritis|url=http://www.controlled-trials.com/ISRCTN21216199|journal=Current Controlled Trials|accessdate=2 October 2013|doi=10.1186/ISRCTN21216199|last1=Fahy|first1=Sarah}}</ref> and [[infliximab]].<ref>{{cite journal|last=Quinn|first=Mark A.|author2=Conaghan, Philip G. |author3=O'Connor, Philip J. |author4=Karim, Zunaid |author5=Greenstein, Adam |author6=Brown, Andrew |author7=Brown, Clare |author8=Fraser, Alexander |author9=Jarret, Stephen |author10= Emery, Paul |title=Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial|journal=Arthritis & Rheumatism|date=January 2005|volume=52|issue=1|pages=27–35|doi=10.1002/art.20712|pmid=15641102}}</ref><ref>{{cite journal|last=Bejarano|first=Victoria|author2=Conaghan, Philip G. |author3=Quinn, Mark A. |author4=Saleem, Benazir |author5= Emery, Paul |title=Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.|journal=Rheumatology|year=2010|volume=49|issue=10|pages=1971–1974|doi=10.1093/rheumatology/keq194|url=http://rheumatology.oxfordjournals.org/content/49/10/1971.long|accessdate=2 October 2013|pmid=20595536}}</ref>
| | * Each "yes" response is scored as '''1'''. |
| | * Each "no" response is scored as '''0'''. |
| | * Total scores are calculated by summing the responses to all 30 items. |
| | * Total scores range from '''0 to 30'''. |
|
| |
|
| == References ==
| | '''Interpretation:''' |
| {{reflist}}
| | * A lower total score indicates a better quality of life and less negative impact of rheumatoid arthritis. |
| | * A higher total score indicates a worse quality of life, suggesting that rheumatoid arthritis has a greater negative impact on the patient's life. |
|
| |
|
| {{DEFAULTSORT:Rheumatoid Arthritis Quality of Life Questionnaire}}
| | ==Clinical Applications== |
| | The RAQoL is useful for: |
| | * Routine clinical assessment to monitor patient progress and response to treatment. |
| | * Clinical trials as an outcome measure to evaluate the effectiveness of new medications or therapeutic interventions. |
| | * Epidemiological studies to understand the broader impact of rheumatoid arthritis within populations. |
| | |
| | ==Advantages== |
| | Key advantages of RAQoL include: |
| | * Disease specificity – tailored explicitly to patients with rheumatoid arthritis. |
| | * Patient-centered – provides direct insights from patients themselves. |
| | * Quick and easy administration – suitable for clinical settings and large-scale studies. |
| | * Reliable and valid measure – supported by clinical validation research. |
| | |
| | ==Limitations== |
| | Despite its benefits, RAQoL has certain limitations: |
| | * Limited depth due to binary "yes/no" responses, potentially oversimplifying complex patient experiences. |
| | * Subjective nature of patient-reported outcomes, influenced by personal interpretations and momentary feelings. |
| | |
| | ==Related Instruments== |
| | Other complementary or alternative patient-reported outcome measures for rheumatoid arthritis include: |
| | * [[Health Assessment Questionnaire]] (HAQ) |
| | * [[Disease Activity Score 28]] (DAS28) |
| | * [[Short Form Health Survey]] (SF-36) |
| | |
| | These tools may be used alongside RAQoL to provide comprehensive assessment of disease severity and impact on patient quality of life. |
| | |
| | ==See Also== |
| | * [[Rheumatoid arthritis]] |
| | * [[Patient-reported outcome measures]] |
| | * [[Quality of life (healthcare)]] |
| | |
| | ==External Links== |
| | * [https://innovation.ox.ac.uk/outcome-measures/rheumatoid-arthritis-quality-life-questionnaire-raqol/ RAQoL Information at Oxford University Innovation] |
| | {{Rheumatology}} |
| | {{Patient-reported outcome measures}} |
| | {{nt}} |
| [[Category:Rheumatology]] | | [[Category:Rheumatology]] |
| | [[Category:Quality of life measures]] |
| | [[Category:Patient-reported outcome measures]] |
| | [[Category:Rheumatoid arthritis]] |
| [[Category:Arthritis]] | | [[Category:Arthritis]] |
| [[Category:Quality of life]]
| |
| {{dictionary-stub1}}
| |
| {{No image}}
| |
Patient-reported outcome measure for rheumatoid arthritis
Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) is a disease-specific, patient-reported outcome measure designed to assess the impact of rheumatoid arthritis (RA) on a patient's quality of life. The RAQoL is widely used in clinical practice and research settings to understand how RA affects daily functioning, emotional well-being, and overall patient satisfaction with life.
Purpose[edit]
The primary purpose of the RAQoL is to quantitatively measure the patient's own perspective regarding how rheumatoid arthritis influences their day-to-day life, emotional health, social interactions, and ability to perform regular tasks. As a self-administered instrument, it helps ensure accuracy by minimizing experimenter bias or error.
Structure[edit]
The RAQoL questionnaire consists of 30 items, each answered with a simple "yes" or "no" response. The questionnaire is designed to be concise and patient-friendly, generally taking approximately six minutes for a patient to complete. This brief and straightforward format allows ease of use in both clinical and research environments.
Each of the 30 items reflects a specific area of life potentially impacted by rheumatoid arthritis, including physical function, emotional health, social participation, and general daily activities.
Scoring[edit]
The scoring method of the RAQoL is straightforward and easy to interpret:
- Each "yes" response is scored as 1.
- Each "no" response is scored as 0.
- Total scores are calculated by summing the responses to all 30 items.
- Total scores range from 0 to 30.
Interpretation:
- A lower total score indicates a better quality of life and less negative impact of rheumatoid arthritis.
- A higher total score indicates a worse quality of life, suggesting that rheumatoid arthritis has a greater negative impact on the patient's life.
Clinical Applications[edit]
The RAQoL is useful for:
- Routine clinical assessment to monitor patient progress and response to treatment.
- Clinical trials as an outcome measure to evaluate the effectiveness of new medications or therapeutic interventions.
- Epidemiological studies to understand the broader impact of rheumatoid arthritis within populations.
Advantages[edit]
Key advantages of RAQoL include:
- Disease specificity – tailored explicitly to patients with rheumatoid arthritis.
- Patient-centered – provides direct insights from patients themselves.
- Quick and easy administration – suitable for clinical settings and large-scale studies.
- Reliable and valid measure – supported by clinical validation research.
Limitations[edit]
Despite its benefits, RAQoL has certain limitations:
- Limited depth due to binary "yes/no" responses, potentially oversimplifying complex patient experiences.
- Subjective nature of patient-reported outcomes, influenced by personal interpretations and momentary feelings.
Related Instruments[edit]
Other complementary or alternative patient-reported outcome measures for rheumatoid arthritis include:
These tools may be used alongside RAQoL to provide comprehensive assessment of disease severity and impact on patient quality of life.
See Also[edit]
External Links[edit]
Rheumatologic diseases[edit]
Arthritis is often used to refer to any disorder that affects the joints. Rheumatic diseases usually affect joints, tendons, ligaments, bones, and muscles. Rheumatologic diseases usually affect joints, tendons, ligaments, bones, and muscles.
Template:Patient-reported outcome measures
